Switch theme
Sign up to access all valuation multiples
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
1999
9.6K+
LTM Revenue $4.1B
LTM EBITDA $1.2B
$34.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DexCom has a last 12-month revenue of $4.1B and a last 12-month EBITDA of $1.2B.
In the most recent fiscal year, DexCom achieved revenue of $3.6B and an EBITDA of $917M.
DexCom expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DexCom valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.6B | $4.0B | $4.1B | XXX |
| Gross Profit | $1.7B | $1.9B | $2.3B | XXX | XXX |
| Gross Margin | 58% | 52% | 57% | XXX | XXX |
| EBITDA | $565M | $917M | $1.2B | $1.2B | XXX |
| EBITDA Margin | 19% | 25% | 29% | 29% | XXX |
| Net Profit | $155M | $341M | $542M | XXX | XXX |
| Net Margin | 5% | 9% | 13% | XXX | XXX |
| Net Debt | $650M | $1.3B | $1.9B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 7, 2025, DexCom's stock price is $88.
DexCom has current market cap of $34.4B, and EV of $34.5B.
See DexCom trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $34.5B | $34.4B | XXX | XXX | XXX | XXX | $1.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 7, 2025, DexCom has market cap of $34.4B and EV of $34.5B.
DexCom's trades at 8.4x LTM EV/Revenue multiple, and 29.1x LTM EBITDA.
Analysts estimate DexCom's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for DexCom and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $34.5B | XXX | XXX | XXX |
| EV/Revenue | 8.6x | XXX | XXX | XXX |
| EV/EBITDA | 29.9x | XXX | XXX | XXX |
| P/E | 50.1x | XXX | XXX | XXX |
| P/E/Growth | 2.4x | XXX | XXX | XXX |
| EV/FCF | 53.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDexCom's NTM/LTM revenue growth is 15%
DexCom's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, DexCom's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate DexCom's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for DexCom and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 43% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 47% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Electromed | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DexCom acquired XXX companies to date.
Last acquisition by DexCom was XXXXXXXX, XXXXX XXXXX XXXXXX . DexCom acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was DexCom founded? | DexCom was founded in 1999. |
| Where is DexCom headquartered? | DexCom is headquartered in United States of America. |
| How many employees does DexCom have? | As of today, DexCom has 9.6K+ employees. |
| Who is the CEO of DexCom? | DexCom's CEO is Mr. Kevin R. Sayer, C.P.A.. |
| Is DexCom publicy listed? | Yes, DexCom is a public company listed on NAS. |
| What is the stock symbol of DexCom? | DexCom trades under DXCM ticker. |
| When did DexCom go public? | DexCom went public in 2005. |
| Who are competitors of DexCom? | Similar companies to DexCom include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem. |
| What is the current market cap of DexCom? | DexCom's current market cap is $34.4B |
| What is the current revenue of DexCom? | DexCom's last 12-month revenue is $4.1B. |
| What is the current EBITDA of DexCom? | DexCom's last 12-month EBITDA is $1.2B. |
| What is the current EV/Revenue multiple of DexCom? | Current revenue multiple of DexCom is 8.4x. |
| What is the current EV/EBITDA multiple of DexCom? | Current EBITDA multiple of DexCom is 29.1x. |
| What is the current revenue growth of DexCom? | DexCom revenue growth between 2023 and 2024 was 11%. |
| Is DexCom profitable? | Yes, DexCom is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
